Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Frequently asked questions
What sector does Immix Biopharma Inc (IMMX) operate in?
Immix Biopharma Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Immix Biopharma Inc (IMMX) current stock price?
As of the latest data, Immix Biopharma Inc stock price is $12.76, with a previous close of $11.81. Immix Biopharma Inc gained $0.95 in the last trading session, representing a 8% increase.
What is Immix Biopharma Inc (IMMX) current market capitalization?
Immix Biopharma Inc market cap is approximately 908.03 million.
What is Immix Biopharma Inc (IMMX) Earnings Per Share (EPS)?
The trailing EPS is -$0.88, and the forward EPS is -$0.84.
What is Immix Biopharma Inc (IMMX) EBITDA?
Immix Biopharma Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -11.54 million.
Does Immix Biopharma Inc (IMMX) pay dividends?
No. Immix Biopharma Inc does not pay a dividend.
What is Immix Biopharma Inc (IMMX) beta (volatility) score?
Immix Biopharma Inc has a beta of 0.111, indicating lower volatility than the overall market.